Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 4 / Episode 2: Dr. Frances Carr
Transcript
- 0:00Just like any machine, the human body relies on multiple moving
- 0:03parts working together in perfect rhythm.
- 0:06The tiny thyroid gland helps control the beat.
- 0:10In today's episode of Isn't That Interesting, we explore
- 0:13groundbreaking research into the connection between thyroid
- 0:17hormone signaling and cancer, and what it could mean for
- 0:21future treatments. Here's Martha Kaley, founder and
- 0:24executive directorofearlier.org. All right, I am so glad that you
- 0:29all could join us to discuss our event here with Doctor Francis
- 0:34Carr. She is a professor of
- 0:36pharmacology at the University of Vermont's Lorner College of
- 0:40Medicine and associate director of the UVM Cancer Center.
- 0:45She is trained in molecular Physiology and endocrinology.
- 0:49Her research centers on how thyroid hormone signaling
- 0:54regulates gene expression, chromatin structure, and cancer
- 0:59biology. I am so excited about your work
- 1:04and about the the thyroid hormone receptor beta because of
- 1:09of opportunity with aggressive thyroid and breast cancer.
- 1:16And so, so and I'll have to say for how we How I Met Doctor Carr
- 1:23was Karen Mcburney, who is our assistant executive director ran
- 1:28into her and met and they were on vacation and so, so obviously
- 1:33they were discussing the whole situation.
- 1:36So then we were able to contact her for this big interview.
- 1:40And I'm just thrilled to have you and to have you share your
- 1:44wisdom and your insights and what you're the promise that
- 1:47you're seeing happen. And that's one of the reasons
- 1:50I'm doing this whole podcast thing is to to help people
- 1:55realize how how many different directions we're coming at
- 2:01identifying impactful things for not diagnosing breast cancer,
- 2:08but also for in the treatment process and how we're going to
- 2:12be altering things accordingly. So I just think this is like a
- 2:15whole Christmas package in it. Everything is just popping out
- 2:19with a gift. So I'm going to let you start,
- 2:22if you don't mind starting with your work with the thyroid
- 2:27receptor and your experience with that, OK.
- 2:31Well, first, thank you so much for the opportunity to have this
- 2:33conversation. We get really excited about the
- 2:36work that we're doing and, and looking forward to finding
- 2:39opportunities to share what we're doing, if you will, in the
- 2:43laboratory and hopefully soon in the clinic with people who are
- 2:47interested in this field, people who might be affected by by
- 2:51cancer and new diagnosis and treatments.
- 2:55So it's really, it's a welcome opportunity for me to have this
- 2:58conversation with you and to see you again.
- 3:00Yeah. I started my work actually long
- 3:03time ago looking at how thyroid hormones actually regulate
- 3:09development and that there is an analysis or an analogy there
- 3:14because thyroid hormones through their recognition molecules, the
- 3:19thyroid hormone receptors, change how our genes are
- 3:24expressed in the proteins that are made and they do it in a
- 3:27very sequential and worded process in development.
- 3:30So I spent my earlier part of my career looking at at that kind
- 3:34of process and thinking about how we start from stem cells and
- 3:39these stem cells eventually differentiate and become full
- 3:44functioning organs. Thyroid hormones are very
- 3:46critical in that process. I spent a number of years doing
- 3:51other things. For a bit, I was a science
- 3:54advisor at the US Agency for International Development.
- 3:57Then I went into university administration for a number of
- 4:01years, including being vice president for research and Dean
- 4:04of the Graduate School at UVM. And I finally got an opportunity
- 4:08to return to my passion. So I went over to restart my
- 4:11laboratory, but this time I did a focus.
- 4:15The flip side of development is cancer.
- 4:18In other words, cancer is development gone awry.
- 4:21So it's going in the opposite direction.
- 4:23So this was an opportunity to take what we had begun to
- 4:28unravel, trying to understand how thyroid hormones regulate
- 4:33development and differentiation and what's happening when we get
- 4:36to cancer. And with cancer, we start off
- 4:39with normal tissues, normal cells that become atypical, as
- 4:44you were just asking me, become atypical and then actually grow
- 4:49without control anymore. But they change from the cells
- 4:54that look like the tissue of origin, thyroid, breast,
- 4:57prostate, whatever, and become become stem cell like cancer
- 5:03stem cells where they lose the expression and characteristics
- 5:07of the tissue. And it's almost the reverse of
- 5:10what happens in development. So we're back to stem cells.
- 5:13So the can't different cancers may look more alike when they're
- 5:18very aggressive because they've become stem cell like.
- 5:21So we became interested in trying to understand what the
- 5:25role thyroid hormones might play in perhaps reversing this
- 5:29process, what could happen in cancer.
- 5:32So without spending too much time going into the overall
- 5:35history, we had started to leverage some wonderful work
- 5:40that was done at the National Cancer Institute by a colleague
- 5:43of mine, Doctor Xian Chang, who had discovered that one of these
- 5:47recognition molecules, thyroid hormone receptor, the beta, not
- 5:52the alpha, she discovered that it was looked like it could
- 5:56without it, cancers would form, thyroid cancers in particular in
- 6:01her model. And so she postulated that it
- 6:04could be a tumor suppressor. So we have leveraged that
- 6:08information and expanded that knowledge and worked diligently
- 6:12over these past years to understand how this receptor
- 6:15could function as a tumor suppressor.
- 6:18And along the way, we discovered in the wonderful way of
- 6:22laboratory science, sometimes, sometimes it's in a moment we
- 6:26were using a molecule as a control for our experiments and
- 6:31that selectively targeted the beta.
- 6:35And we had the moment saying, oh, why can't we move this to
- 6:39the clinic and see if this molecule could be effective
- 6:43clinically. So without going on more and
- 6:45more, that's kind of the basis of our work.
- 6:48And I'd also like to say that in the hormone receptor field, most
- 6:53people have heard of estrogen receptor and that's so
- 6:57characteristic of breast cancers, ER positive and they
- 7:00mean ER alpha positive because there is a beta progesterone
- 7:04receptor. So you have ER, PR,
- 7:07glucocorticoid receptor and androgen receptor have all
- 7:11become more prominent as therapeutic targets,
- 7:14particularly in breast cancer, but other cancers as well.
- 7:17And another member of that family, which seems to be, if
- 7:21you will, the orphan child not brought into the conversation.
- 7:25So thyroid hormone receptor, they're all part of the same
- 7:28complex family. They are, these receptors
- 7:31actually have a common evolutionary origin.
- 7:34So then they became all of this family of steroid receptors and
- 7:38thyroid receptors. So we don't use thyroid
- 7:41receptors clinically, diagnostically yet hopefully we
- 7:45will and also as therapeutic targets.
- 7:48But so that's sort of the big picture of how we got here.
- 7:52And we have spent my research group, I'm very fortunate to
- 7:56have wonderful students in there and we are really working
- 7:59diligently to understand how this thyroid hormone action
- 8:04through the thyroid hormone receptor beta regulates the
- 8:08genome, the epigenome, the proteins that are made and
- 8:12particularly targets those cancer stem cells.
- 8:15So that's that's a long introduction to how we got here.
- 8:19Well, I, I just keep thinking in my mind and from what I read
- 8:26there are, we know that there are indicators that we can
- 8:31identify and it's like that through the blood and saliva and
- 8:35urine about like the DNA methylation.
- 8:39And so that we see those indicators and yet we don't, I
- 8:44don't think that we, well, we don't have a way of really
- 8:48understanding yet where we transition from one point to the
- 8:54other. And that's why I think your work
- 8:56is probably getting closer to understanding how those normal
- 9:02cells transition. And it's like for with breast
- 9:06cancer, with the breast density being such a consideration for
- 9:13breast cancer. And yet, you know, you get
- 9:16everybody, all the most people get these letters saying, well,
- 9:19you got dense breast tissue, But so I guess you just need to
- 9:23watch out for it. But that doesn't make me happy,
- 9:26isn't it? That's that's, you know, kind of
- 9:30an afterthought. I would like for us to
- 9:33understand if that breast tissue changes from normal tissue to
- 9:38atypical and if the atypical, does it always change to being
- 9:43breast cancer or does it doesn't always change to being breast
- 9:47cancer? And yet, so, so where can we
- 9:50pick up the interception of that?
- 9:52So that's my that's where I come in with all of this and how you
- 9:57might be able to help me understand that better.
- 10:00I think we're beginning to understand more and more of just
- 10:03what you're saying. How do we what happens when a
- 10:05normal cell starts to become a typical and where are the checks
- 10:11and balances to keep it from progressing to a cancer and how
- 10:14do you distinguish between that? We're really fortunate
- 10:17physiologically that we it happens all the time.
- 10:20We have atypical cells certainly going out and getting a sunburn
- 10:23and things like that. The DNA gets damaged and the
- 10:27cells become atypical. But we have multiple mechanisms
- 10:31where we get rid of those cells. So we have program cell death,
- 10:36We have DNA repair enzymes. So a lot of that, we don't even
- 10:40notice what's happening in our bodies because our bodies take
- 10:43care of and get rid of these atypical cells.
- 10:46But a number of factors come into play.
- 10:48And you mentioned DNA methylation.
- 10:51What sometimes happens is that in addition to mutations, which
- 10:55we know about DNA, mutations can contribute to this, but we can
- 11:00have changes in the epigenome, the proteins.
- 11:04DNA, of course, is surrounded in, in a coil around proteins.
- 11:08And there are more proteins that keep the DNA in context, in
- 11:11chromatin as we describe it. And so damage to those proteins
- 11:17or changes in those proteins can make DNA that has been tightly
- 11:21closed and regulated and make it more open.
- 11:25And all of a sudden, these genes are available to become is made
- 11:29copies and proteins made so they can be transcribed.
- 11:33So changes to the proteins that keep the the DNA compact can
- 11:39affect whether or not they'll be uncontrolled gene expression,
- 11:44uncontrolled making of proteins. And that can occur in a lot of
- 11:48different ways. You mentioned methylation.
- 11:51Their methylation can be DNA methylation or it can be changes
- 11:55on the proteins of themselves. Methylation and acetylation, a
- 11:59lot of modifications, chemical modifications have those
- 12:02proteins. So if we think about those being
- 12:05able to be dysregulated and all of a sudden genes that are
- 12:10supposed to be not expressed into proteins are now available
- 12:14to be made into proteins, oncogenes in particular that,
- 12:18you know, the tumor promoters, then we have a damaged cell that
- 12:22may not be able to be fixed or killed.
- 12:26So how does this happen? So we could have changes in the
- 12:29epigenome through lifestyle, environmental factors.
- 12:34You can have other proteins that become dysregulated that have
- 12:37downstream effects. A lot of those proteins in the
- 12:40epigenome are actually enzymes. So if one of those gets damaged,
- 12:44it may not be able to regulate all of the other proteins.
- 12:48But there's more and more evidence that exposures to
- 12:52environmental toxins in particular can impact how these
- 12:56proteins are around the DNA. And importantly, that means that
- 13:02regulation of gene expression can be distorted.
- 13:07If we think about two things, I find a very important one is if
- 13:11we think about the most aggressive cancers and if we
- 13:15look at DNA in the cell where it's, you know, can be closed in
- 13:19different places, it's very regular.
- 13:22And what happens in the stem cells is that it has what we
- 13:26call chromosome instability. There's a lot of open chromatin.
- 13:30Genes are being copied. Proteins are being made that
- 13:33aren't supposed to be made, those that are supposed to be
- 13:37made or have now become closed. So there's a lot of
- 13:40dysregulation that happens, importantly, whether you know
- 13:43some of our dietary or environmental exposures, and we
- 13:47get these changes in these proteins.
- 13:49The second thing I think it's most important to keep in mind
- 13:52is those changes in the epigenome can be inherited.
- 13:56So while I may be exposed to an environmental toxin, you know,
- 14:01middle age, it may not, you know, express itself as a cancer
- 14:06for me, but it might for my daughter or my son or my
- 14:11grandchildren because that's like a first vulnerability.
- 14:15And then they get a second vulnerability or a second, you
- 14:18know, exposure. Maybe it's radiation, maybe it's
- 14:22disease or a virus, and that causes an instability.
- 14:26So we have to think about this in the generational context as
- 14:30well. So I didn't mean to go on for so
- 14:32long about the epigenome. No, I and as far as I'm
- 14:36concerned, that's not long because I think the Epigenome is
- 14:39just something that it's, it can be very telling.
- 14:44I think it's a real indicator for giving us insight into what
- 14:51we really can be looking at. And I just, so how about with
- 14:55the micro RNAs? And I know that that's being
- 14:58studied a lot and, and I want your confirmation one or the
- 15:02other, what I know they're looking at it.
- 15:06And one thing I was reading was it's pretty unstable, but other
- 15:12other work seems to not be distracted by that.
- 15:15What's your what's your impression about the micro RNA
- 15:19and and its impact on on the epigenome?
- 15:22It's, it's interesting that Ray said, we, we actually did some
- 15:25work which I hope will have some impact.
- 15:29It's some on micro RNAs. We were looking at tiny
- 15:34microcarcinomas of the thyroid and this, it's actually an
- 15:38important policy, health policy question now because when you
- 15:42have these little tiny microcarcinomas, thyroid, breast
- 15:46or whatever, there's a lot of discussion as to whether or not
- 15:50you should just ignore them and you know, wait to see if
- 15:53something happens. We had looked at these
- 15:55microcarcinomas on their micro RNA profiles and we were
- 16:00specifically looking at these because we had some of these we
- 16:05had found because the primary cancer was discovered because of
- 16:10a metastasis. So what happened was the little
- 16:14microcarcinomas papillary, so generally the least aggressive
- 16:18form. Some are indolent and some are
- 16:21very aggressive, but the primary sites never grow, so they stay
- 16:24as microcarcinomas. So we'd call them sort of the
- 16:28bad actors or the not so bad actors, the benign versus the
- 16:32aggressive. And so we had metastasis with
- 16:35the aggressive and again no growth in the primary side.
- 16:38So we decided to take a look at the micro RNA profiles for a
- 16:42couple of reasons. One is because those micro RNAs
- 16:45can in fact protein affect translation into protein.
- 16:49So they affect protein stability and we were looking at it from
- 16:52that perspective, but also because many of these micro RNAs
- 16:56can be detected in blood samples, so you know, they're
- 16:59small and can circulate. So we actually developed a
- 17:02diagnostic to distinguish between indolent and aggressive
- 17:06microcarcinomas. And we hope someday that you
- 17:10know some company will be interested in actually taking
- 17:13that and bringing it into into a clinical place.
- 17:17We've already demonstrated that it works and those are fine.
- 17:20So I feel that they can have tremendous value.
- 17:24We had experience with it and we know it can be a diagnostic.
- 17:28We'd like to see that in a clinical trial from to detect
- 17:32these micro RNAs in patient samples.
- 17:34And I hope someday that will happen.
- 17:36So I believe they can be very important.
- 17:39Yes, I agree. Well, tell me about and I don't
- 17:42want to take up too much of your time, but tell me about what you
- 17:45see on the homestretch here, what you're looking at as you've
- 17:50been discovering things as I understand.
- 17:52So talk to me about the stem cell and what what you're
- 17:55finding. So I love being able to be at
- 17:59this place with my with my students where we're working
- 18:03very hard to understand how tier Beta is working as a tumor
- 18:06suppressor. In the meantime, we've been
- 18:08trying to accelerate over into the clinic as well with this the
- 18:12first class drug that we have. And what we've discovered is
- 18:17that in that the molecule that interacts with the TR beta
- 18:23actually seems to have its most prominent effect on the cancer
- 18:28stem cells. And the cancer stem cells are
- 18:30the ones that really are at the forefront for metastasis and
- 18:35also for developing drug resistance.
- 18:37Again, they become more like, you know, stem cells as opposed
- 18:42to the cell of the tissue of origin.
- 18:45And importantly, if we think about it, the, the most of the
- 18:50therapies, not all, but most of the therapies that are in common
- 18:54usage actually target enzymes or functions within a cell that is
- 19:01more normal like so tyrosine kinase inhibitors and things
- 19:05like that. They target specific pathways.
- 19:08Well, those aren't necessarily the drivers in the cancer stem
- 19:12cells. And so, and in collaboration I
- 19:15have with the breast cancer team now at UVM, I'd ask, well, what
- 19:20percentage of your, when you're doing a biopsy, what percentage
- 19:24of the biopsy cells are actually stem cells?
- 19:28Well, they don't look for that. And I said, well, well, OK, all
- 19:33right, we need to be looking at that as a diagnostic.
- 19:36But what we've discovered is that our candidate drug, so
- 19:40vitorome GC one through TR beta shuts down the cancer stem
- 19:44cells. And importantly one of the
- 19:46things that we have discovered is that the action of TR beta in
- 19:52a kind of a simple by simple mode is that it actually induces
- 19:58differentiation. And we can show this.
- 20:00And then we've shown this in our thyroid cancer models where the
- 20:04cells are very, the cancer cells are the human cancer cell lines
- 20:08we look at and tumor studies are all with the human tumors.
- 20:12What happens is that we lose the expression of the proteins
- 20:15typical of the thyroid cell and when we treat with our GC one
- 20:20with our drug and activate TR beta, it causes re expression of
- 20:25the proteins that are typically there.
- 20:27And why that matters is that, for example, with thyroid
- 20:31cancer, the typical treatment of less aggressive thyroid cancer
- 20:36is to treat with radioactive iodine.
- 20:39And that's because there are proteins on the outside of the
- 20:42cells of transporter, sodium iodide transporter that actively
- 20:47takes up, normally takes up iodine into the thyroid cell
- 20:51because it's needed to make thyroid hormones.
- 20:53So this protein is there. It's also there in breast cells.
- 20:56So what happens in the cancer stem cells is that expression is
- 21:01almost gone. If not it's not detectable and
- 21:05activation of TR beta causes the re expression of this protein
- 21:10and we've shown that it's functional and can take up
- 21:12iodine. So that means that what we're
- 21:15seeing here and then we're actually just, we're just about
- 21:18to publish this is it actually causes a reprogramming the
- 21:23taking advantage of plasticity and reprograms these cancer stem
- 21:27cells in these aggressive atypical cells back towards a
- 21:31more say normal cell like. And when you have that as more
- 21:36normal cell like, you can actually use a combination
- 21:39therapy like using our TR beta activator and it re
- 21:44differentiates and now you can come in and hit it with
- 21:46radioactive iodine if that's the, you know, the cancer that
- 21:50you're treating. We've also shown this for breast
- 21:52cancers so that now you can actually go back and use
- 21:55tamoxifen again. So we're able to increase the
- 22:00effectiveness of typical therapeutics by driving
- 22:04reprogramming of these cells. And that's what we're excited
- 22:08about is we can really see what's happening now with the
- 22:11cancer stem cells have done all of these sequencing things to
- 22:14try to understand exactly what the programs are that are are
- 22:18changing. And we've just completing
- 22:20another tumor study in using our mouse models to show that, Yep,
- 22:25we can shut down those tumors that are being driven by the
- 22:29stem cells. So that's important because,
- 22:31well, first of all, it's great to get rid of the stem cells.
- 22:34And secondly, it's they, there aren't that many therapies that
- 22:38specifically target the cancer stem cells.
- 22:42One partner of the thyroid hormone receptor may in fact be
- 22:46another hormone receptor in this this family and it's a retinoid
- 22:51retinoic acid receptor. The they are and you can target
- 22:55that receptor with a molecule and it's in the clinic for blood
- 22:59cancers and it's called ATRA. And what we're finding is you
- 23:03can actually there probably is a relationship between the two.
- 23:08We're working to understand that we think TR beta may be driving
- 23:12the RAR as part of how TR beta works.
- 23:15But nevertheless, we're exploiting the possibility that
- 23:18we could have new combinations with these, with these types of
- 23:22drugs. That's really.
- 23:24Excited. About the stem cell, it really
- 23:26is. Remarkable.
- 23:28I just think that's a real big step for evaluating and
- 23:33analyzing what's going on. And I just, it's so exciting to
- 23:38think about that we're looking at through research.
- 23:41Oh my goodness, we're just evolving so many different
- 23:44routes to to see things and I think you're just leading the
- 23:49pack on this. I really appreciate all of the
- 23:52work that you you have done and are continuing to do with the
- 23:57with this, because I think this is a real potential breakthrough
- 24:00for us and how we can how we can develop and grow with that.
- 24:04So I really appreciate that. Thank you We.
- 24:08We're excited about two. Two things are in the near
- 24:12future here. 1 is that we've applied to the FDA for approval
- 24:16for what's called a rare cancer designation.
- 24:19We've been looking at the aggressive thyroid cancers as
- 24:22our first model because there are no effective therapies known
- 24:26during therapies now. So even though it's a relatively
- 24:29rare cancer, this class, there aren't any treatments.
- 24:32So we're trying to get something out there.
- 24:34So the molecule that we're using right now is a first in class
- 24:37will be designated as a Morphin drug with that process going
- 24:42through. So we're excited about that.
- 24:44The the second piece is that my colleagues in the breast cancer
- 24:48team here at UVM, we are exploring the opportunity to do
- 24:52what's referred to as a window of opportunity trial in breast
- 24:55cancer. So we know that it's it should
- 24:59work, but the idea that we can leverage the prior work that's
- 25:03been done in terms of clinical trials using this molecule for
- 25:07other diseases that we'll be able to advance quickly a window
- 25:12of opportunity clinical trium breast cancer and we're
- 25:14targeting that for the fall. So that we feel very excited
- 25:18about both of these opportunities coming in front of
- 25:21us. I have to give a shout out to
- 25:23thyroid hormones because, you know, they've been part of my
- 25:28life for a long time. But the molecule that we're
- 25:31using is a synthetic thyroid hormone.
- 25:33It's orally bioavailable. It was developed by an
- 25:36investigator, Tom Scanlon, now at Oregon Health Sciences.
- 25:41And he developed a class of these molecules because he and
- 25:44other folks have been looking at how TR beta selective molecules
- 25:49could treat metabolic diseases of the liver.
- 25:52So we basically got access to this molecule that had been in
- 25:55clinical trials and said, hey, wait, it's working for tumors.
- 25:59And so we've been able to advance that.
- 26:01But I just for those folks who are looking at thyroid hormone
- 26:04receptor beta agonist, they have them in clinical trials now for
- 26:08multiple sclerosis, a lot of neurodevelopmental disorders.
- 26:12And so if we just go back to that, my simple analogies,
- 26:15thyroid hormones are critical for differentiation and the
- 26:20disorders we're talking about, we have lost the characteristics
- 26:23of the tissues, whether it's because of a cancer or it's
- 26:26because of our neuro disease, that of the myelin sheets and
- 26:31things like that. It's kind of taking advantage of
- 26:34how we understand basically how these molecules work in the
- 26:38first place in development and sort of leveraging that for, OK,
- 26:42let's harness back, let's bring that cancer back to a more
- 26:45normal state. Fabulous.
- 26:47That just really sounds so exciting and could you just
- 26:51hurry up and get that finished for us?
- 26:53OK, I'm heading into. The lab now, OK, I've already
- 26:56texted my students, said I'm coming in late, I'm having a
- 26:59conversation. Well, tell your students.
- 27:01I'm very proud of them because obviously you all are doing
- 27:04them. One wonderful.
- 27:06Work so I thank you so much for sharing with us and being
- 27:10willing to to share with us and I can't wait for our listeners
- 27:15to they don't have to understand everything.
- 27:18I think that that that's some of the turn off is when you listen
- 27:22to science, you think, oh, I have to understand it.
- 27:24Well, you don't have to understand it all.
- 27:26You just have to pick up little snippets and know that this is
- 27:30really promising. And these are things that that
- 27:32is developmental thing. And I just thank you so much for
- 27:36sharing that and. And your.
- 27:38Work so and we will look forward to talking with you again soon.
- 27:44I hope so. Take good care, Martha, and
- 27:46thank you for the opportunity to be with you today.
- 27:47Thank you. OK, bye bye, bye, bye this.
- 27:51Episode. Of Isn't that Interesting was
- 27:53made possible thanks to volunteers and donors just like
- 27:56you. It was hosted by Martha Kaley,
- 27:58founderofearlier.org and edited by Liam Mcburney.
- 28:03I'm Valerie Amsterdam, reminding you that for the last 30 years,
- 28:07this is North Carolina based organization has helped fund
- 28:10groundbreaking research all over the world from molecular imaging
- 28:14to a sensitive blood test for breast cancer.
- 28:17Plain and simple, earlier detection saves lives.
- 28:20And you can help host a fundraising event, make a
- 28:23donation for volunteer your time.
- 28:25You can find us not only on the web, but on Facebook and
- 28:28Instagram too. Let's change the picture of
- 28:31breast cancer together.